NCT01001572
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
See it on ClinicalTrials.gov ↗651 people
44.7%
55.3%
291 womenmiddle line = equal numbers360 men
- Phase
- PHASE3
- Paid for by
- Novartis
- Finished
- 2010-05
- Health conditions
- Essential Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 53.0 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Evidence of secondary form of hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma or polycystic kidney disease )”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, myocardial infarction or all types of revascularization, angina pectoris of any type, including unstable angina”
- No cancer
Women with current or past cancer were turned away.
“Malignant hypertension”
Study titles and rules are shown in their original English.